Patents Examined by D. L. Jones
  • Radioactive labeling method for neuropeptide Y derivative compound and medicine for multi-type breast cancer therapy thereof
    Patent number: 11077217
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga67Ga68Ga177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: August 3, 2021
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Methods for diagnosing and monitoring eosinophilic esophagitis
    Patent number: 11065351
    Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 20, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Leonard F. Pease, Hedieh Saffari, Gerald J. Gleich, Kristin M. Leiferman, Kathryn A. Peterson, Russell Morris Condie
  • HSP90-targeted inflammation and infection imaging and therapy
    Patent number: 11065350
    Abstract: The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 20, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mark Dunphy, Gabriela Chiosis
  • Carbonic anhydrase targeting agents and methods of using same
    Patent number: 11059802
    Abstract: The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 13, 2021
    Assignee: VisEn Medical, Inc.
    Inventors: Kevin Groves, Bagna Bao
  • Diazacarbazole derivatives as tau-PET-ligands
    Patent number: 11058781
    Abstract: The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, besides others, beta-amyloid aggregates or alpha-synuclein aggregates.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 13, 2021
    Inventors: Luca Gobbi, Henner Knust, Matthias Koerner, Dieter Muri
  • Fluorescent compounds
    Patent number: 11053222
    Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: July 6, 2021
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
  • Selective delivery molecules and methods of use
    Patent number: 11052160
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion DA and DB).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 6, 2021
    Assignee: Avelas Biosciences, Inc.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Homing agents
    Patent number: 11052163
    Abstract: The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 6, 2021
    Assignee: Washington University
    Inventors: Gregory M. Lanza, Samuel I. Achilefu, Grace Hufang Cui
  • Peptide amide compound and preparation method and medical use thereof
    Patent number: 11014964
    Abstract: The invention provides a peptide amide compound represented by the general general formula (I), a preparation method thereof, and a medical application thereof. The compound has a novel structure, better biological activity, and better analgesic effect.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 25, 2021
    Assignee: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen Zhang, Anbang Huang, Fei Ye, Longbin Huang, Zhenggang Huang, Jianmin Wang, Yonggang Wei, Pangke Yan, Wei Zheng
  • Compositions and methods for treatment and imaging using nanoparticles
    Patent number: 11007286
    Abstract: The present invention encompasses compositions comprising two spectrally distinct radionuclides separated by a site susceptible to cleavage. Compositions of the invention may be used to detect enzyme activity and/or image diseases associated with said enzyme activity.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: May 18, 2021
    Assignee: Washington University
    Inventors: Samuel Achilefu, Kvar Black
  • 177-Lu labeled peptide for site-specific uPAR-targeting
    Patent number: 10994032
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 4, 2021
    Assignee: TRT Innovations APS
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
  • Methods and compositions for protection of cells and tissues from computed tomography radiation
    Patent number: 10987366
    Abstract: Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 27, 2021
    Assignee: The University of Chicago
    Inventor: David J. Grdina
  • Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
    Patent number: 10988534
    Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 27, 2021
    Assignees: Memorial Sloan Kettering Cancer Center, Massachusetts Institute of Technology
    Inventors: Sarah Cheal, Hong Xu, Steven Larson, Nai-Kong Cheung, Karl Dane Wittrup, Alice Tzeng
  • Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents
    Patent number: 10981866
    Abstract: The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein the definitions of R1-R12 and L1-L4 are provided in the disclosure, wherein R13 is a chelating group comprising 177Lu, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 20, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Methods and compositions for theranostic nanoparticles
    Patent number: 10973925
    Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 13, 2021
    Assignees: University of Central Florida Research Foundation Inc., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Memorial Sloan Kettering Cancer Center
    Inventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
  • Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives
    Patent number: 10975073
    Abstract: The invention relates to small molecule imaging tools.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Non-aggregating heptamethine cyanine fluorophores for in vivo imaging
    Patent number: 10961193
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy
    Patent number: 10960048
    Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 30, 2021
    Assignee: Guard Therapeutics International AB
    Inventors: Bo Åkerström, Sven-Erik Strand, Magnus Göran Gram, Amanda Thuy Tran
  • Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
    Patent number: 10947275
    Abstract: The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticle pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 16, 2021
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Ayelet David, Gonen Ashkenasy, Yosi Shamay
  • Molecular probes and methods of use
    Patent number: 10925980
    Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: February 23, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Zheng-Rong Lu, Zheng Han